| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,040 |
14,222 |
$2.36M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,837 |
5,427 |
$1.20M |
| S9083 |
Global fee urgent care centers |
6,096 |
5,719 |
$714K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
17,548 |
13,579 |
$635K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
13,718 |
13,213 |
$320K |
| 99215 |
Prolong outpt/office vis |
1,697 |
1,639 |
$230K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,305 |
1,249 |
$169K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
9,756 |
9,441 |
$154K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
877 |
836 |
$141K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
400 |
368 |
$81K |
| 71046 |
Radiologic examination, chest; 2 views |
1,151 |
1,120 |
$71K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
636 |
611 |
$63K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,221 |
1,178 |
$61K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
855 |
799 |
$58K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
560 |
534 |
$52K |
| 99205 |
Prolong outpt/office vis |
310 |
301 |
$49K |
| 81001 |
|
1,349 |
1,303 |
$16K |
| 73610 |
|
79 |
74 |
$12K |
| 73630 |
|
73 |
73 |
$6K |
| 94664 |
|
667 |
626 |
$6K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
35 |
32 |
$5K |
| 84703 |
|
39 |
38 |
$3K |
| 87807 |
|
239 |
217 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
162 |
149 |
$2K |
| 73140 |
|
13 |
13 |
$2K |
| 74019 |
|
21 |
16 |
$1K |
| 87581 |
|
114 |
104 |
$912.56 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
68 |
59 |
$912.07 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
719 |
686 |
$423.89 |
| 87077 |
|
53 |
50 |
$300.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
644 |
618 |
$66.93 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
92 |
91 |
$63.94 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
74 |
70 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
120 |
114 |
$0.00 |
| 87486 |
|
52 |
48 |
$0.00 |